Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial

The Lancet Oncology ◽

10.1016/s1470-2045(14)70455-3 ◽

2014 ◽

Vol 15 (12) ◽

pp. 1311-1318 ◽

Author(s):

Nathan H Fowler ◽

R Eric Davis ◽

Seema Rawal ◽

Loretta Nastoupil ◽

Fredrick B Hagemeister ◽

...

Keyword(s):

Phase 2 ◽

Indolent Lymphoma ◽

Phase 2 Trial ◽

Open Label Phase

Download Full-text

Dose-Adjusted EPOCH Regimen as First-Line Treatment for Non-Hodgkin's Lymphoma with Hemophagocytic Lymphohistiocytosis: A Single-Arm, Open-Label, Phase 2 Trial

SSRN Electronic Journal ◽

10.2139/ssrn.3304299 ◽

2018 ◽

Author(s):

Jin-Hua Liang ◽

Li Wang ◽

Hua-Yuan Zhu ◽

Jun Qian ◽

Hui Liao ◽

...

Keyword(s):

Hemophagocytic Lymphohistiocytosis ◽

Hodgkin's Lymphoma ◽

Line Treatment ◽

Phase 2 ◽

Phase 2 Trial ◽

Non Hodgkin's Lymphoma ◽

Open Label Phase ◽

First Line Treatment

Download Full-text

Switch-maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma (NVALT19): an investigator-initiated, randomised, open-label, phase 2 trial

The Lancet Respiratory Medicine ◽

10.1016/s2213-2600(20)30362-3 ◽

2021 ◽

Author(s):

Cornedine J de Gooijer ◽

Vincent van der Noort ◽

Jos A Stigt ◽

Paul Baas ◽

Bonne Biesma ◽

...

Keyword(s):

Malignant Mesothelioma ◽

Phase 2 ◽

Phase 2 Trial ◽

Open Label Phase ◽

Line Chemotherapy

Download Full-text

Dexamethasone plus oseltamivir versus dexamethasone in treatment-naive primary immune thrombocytopenia: a multicentre, randomised, open-label, phase 2 trial

The Lancet Haematology ◽

10.1016/s2352-3026(21)00030-2 ◽

2021 ◽

Vol 8 (4) ◽

pp. e289-e298 ◽

Author(s):

Lu Sun ◽

Juan Wang ◽

Linlin Shao ◽

Chenglu Yuan ◽

Hongguo Zhao ◽

...

Keyword(s):

Immune Thrombocytopenia ◽

Phase 2 ◽

Phase 2 Trial ◽

Primary Immune Thrombocytopenia ◽

Open Label Phase ◽

Treatment Naïve

Download Full-text

Faculty Opinions recommendation of [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.739562946.793583755 ◽

2021 ◽

Author(s):

Patrick Richard

Keyword(s):

Prostate Cancer ◽

Phase 2 ◽

Castration Resistant Prostate Cancer ◽

Phase 2 Trial ◽

Castration Resistant ◽

Open Label Phase

Download Full-text

Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial

10.1016/s0140-6736(14)61795-5 ◽

2015 ◽

Vol 385 (9973) ◽

pp. 1075-1086 ◽

Author(s):

Eric Lawitz ◽

Edward Gane ◽

Brian Pearlman ◽

Edward Tam ◽

Wayne Ghesquiere ◽

...

Keyword(s):

Hepatitis C Virus ◽

Hepatitis C ◽

Phase 2 ◽

Efficacy And Safety ◽

Virus Genotype ◽

Phase 2 Trial ◽

Open Label Phase ◽

Download Full-text

Substitution of ethambutol with linezolid during the intensive phase of treatment of pulmonary tuberculosis: a prospective, multicentre, randomised, open-label, phase 2 trial

The Lancet Infectious Diseases ◽

10.1016/s1473-3099(18)30480-8 ◽

2019 ◽

Vol 19 (1) ◽

pp. 46-55 ◽

Author(s):

Jung-Kyu Lee ◽

Ji Yeon Lee ◽

Deog Kyeom Kim ◽

Ho Il Yoon ◽

Ina Jeong ◽

...

Keyword(s):

Pulmonary Tuberculosis ◽

Phase 2 ◽

Intensive Phase ◽

Phase 2 Trial ◽

Open Label Phase

Download Full-text

Oral all-trans retinoic acid plus danazol versus danazol as second-line treatment in adults with primary immune thrombocytopenia: a multicentre, randomised, open-label, phase 2 trial

The Lancet Haematology ◽

10.1016/s2352-3026(17)30170-9 ◽

2017 ◽

Vol 4 (10) ◽

pp. e487-e496 ◽

Author(s):

Fei-Er Feng ◽

Ru Feng ◽

Min Wang ◽

Jia-Min Zhang ◽

Hao Jiang ◽

...

Keyword(s):

Immune Thrombocytopenia ◽

Line Treatment ◽

Second Line ◽

Phase 2 ◽

Phase 2 Trial ◽

Trans Retinoic Acid ◽

All Trans Retinoic Acid ◽

Primary Immune Thrombocytopenia ◽

Open Label Phase

Download Full-text

Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial

The Lancet Oncology ◽

10.1016/s1470-2045(20)30111-x ◽

2020 ◽

Vol 21 (5) ◽

pp. 655-663 ◽

Author(s):

Sarah B Goldberg ◽

Kurt A Schalper ◽

Scott N Gettinger ◽

Amit Mahajan ◽

Roy S Herbst ◽

...

Keyword(s):

Brain Metastases ◽

Long Term Results ◽

Phase 2 ◽

Phase 2 Trial ◽

Biomarker Analysis ◽

Open Label Phase

Download Full-text

Erlotinib Versus Etoposide/Cisplatin With Radiation Therapy in Unresectable Stage III Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer: A Multicenter, Randomized, Open-Label, Phase 2 Trial

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/j.ijrobp.2020.11.026 ◽

2020 ◽

Author(s):

Ligang Xing ◽

Gang Wu ◽

Luhua Wang ◽

Jiancheng Li ◽

Jianhua Wang ◽

...

Keyword(s):

Lung Cancer ◽

Growth Factor Receptor ◽

Phase 2 ◽

Small Cell Lung ◽

Phase 2 Trial ◽

Unresectable Stage ◽

Open Label Phase ◽

Epidermal Growth

Download Full-text

Correction: Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial

Journal for ImmunoTherapy of Cancer ◽

10.1136/jitc-2020-000798corr1 ◽

2020 ◽

Vol 8 (1) ◽

pp. e000798corr1

Keyword(s):

Phase 2 ◽

Phase 2 Trial ◽

Open Label Phase

Download Full-text